Skip to main content

Articles

Page 3 of 73

  1. Malignant ascites commonly occurs in advanced or recurrent stages of epithelial ovarian cancer during peritoneal carcinomatosis and is correlated with poor prognosis. Due to its complex composition of cellular...

    Authors: Antonio Hrvat, Mathias Schmidt, Bernd Wagner, Denise Zwanziger, Rainer Kimmig, Lothar Volbracht, Sven Brandau and Nina Mallmann-Gottschalk
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:235
  2. Neoadjuvant radiotherapy has been used as the standard treatment of colorectal cancer (CRC). However, radiotherapy resistance often results in treatment failure. To identify radioresistant genes will provide n...

    Authors: Tingting Liu, Hang Wang, Yuanyuan Chen, Zhijie Wan, Zhipeng Du, Hui Shen, Yue Yu, Shengzhe Ma, Ying Xu, Zhuqing Li, Nanxi Yu, Fangxiao Zhang, Kun Cao, Jianming Cai, Wei Zhang, Fu Gao…
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:234
  3. Sec23 homolog A (SEC23A), a core component of coat protein complex II (COPII), has been reported to be involved in several cancers. However, the role of SEC23A in gastric cancer remains unclear.

    Authors: Quan Cheng, Kanghui Liu, Jian Xiao, Kuan Shen, Yuanhang Wang, Xinyi Zhou, Jiawei Wang, Zekuan Xu and Li Yang
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:232
  4. Acute lymphoblastic leukemia (ALL) is the most common pediatric hematological malignancy, with ETV6::RUNX1 being the most prevalent translocation whose exact pathogenesis remains unclear. IGF2BP1 (Insulin-like Gr...

    Authors: Gunjan Sharma, Tiffany M. Tran, Ishu Bansal, Mohammad Sabique Beg, Ruchi Bhardwaj, Jaspal Bassi, Yuande Tan, Amit Kumar Jaiswal, Christine Tso, Ayushi Jain, Jay Singh, Parthaprasad Chattopadhyay, Archna Singh, Anita Chopra, Sameer Bakhshi, David Casero…
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:231
  5. Most of the endometrial cancer (EC) patients are diagnosis in early stage with a good prognosis while the patients with locally advanced recurrent or metastatic result in a poor prognosis. Adjuvant therapy cou...

    Authors: Xi Chen, Xin Liu, Qian-hui Li, Bing-feng Lu, Bu-min Xie, Yu-meng Ji and Yang Zhao
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:230
  6. As a subclass of endogenous stable noncoding RNAs, circular RNAs are beginning to be appreciated for their potential as tumor therapeutics. However, the functions and mechanisms by which circRNAs exert protect...

    Authors: Deze Zhao, Yeping Dong, Minghao Duan, Dan He, Qun Xie, Wei Peng, Weifang Cui, Junjie Jiang, Yuanda Cheng, Heng Zhang, Faqing Tang, Chunfang Zhang, Yang Gao and Chaojun Duan
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:229
  7. Accumulating evidence has demonstrated that aberrant expression of deubiquitinating enzymes is associated with the initiation and progression of Triple-negative breast cancer (TNBC). The publicly available TCG...

    Authors: Zhitao Han, Qi Jia, Jing Zhang, Miaomiao Chen, Lining Wang, Kai Tong, Weiwei He, Yajie Zhang, Weina Zhu, Ju Qin, Tao Wang, Tielong Liu, Yong Ma, Yuanming Chen, Siluo Zha and Chunlei Zhang
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:228
  8. Breast cancer (BC) is the leading cause of morbidity and the second leading cause of death among female malignant tumors. Although available drugs have been approved for the corresponding breast cancer subtype...

    Authors: Hong Yang, Xiangjin Zhen, Yihui Yang, Yizhi Zhang, Sen Zhang, Yue Hao, Guanhua Du, Hongquan Wang, Bailin Zhang, Wan Li and Jinhua Wang
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:227
  9. Breast cancer is one of the frequent tumors that seriously endanger the physical and mental well-being in women. F-box and WD repeat domain-containing 7 (FBXW7) is a neoplastic repressor. Serving as a substrat...

    Authors: Siyu Chen, Ping Leng, Jinlin Guo and Hao Zhou
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:226
  10. Tumors have evolved in various mechanisms to evade the immune system, hindering the antitumor immune response and facilitating tumor progression. Immunotherapy has become a potential treatment strategy specifi...

    Authors: Hongli Gao, Jianqiao Yin, Ce Ji, Xiaopeng Yu, Jinqi Xue, Xin Guan, Shuang Zhang, Xun Liu and Fei Xing
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:225
  11. FAT4 (FAT Atypical Cadherin 4) is a member of the cadherin-associated protein family, which has been shown to function as a tumor suppressor by inhibiting proliferation and metastasis. The Wnt/β-catenin pathwa...

    Authors: Dongying Wang, Shuying Wu, Jiaxing He, Luguo Sun, Hongming Zhu, Yuxuan Zhang, Shanshan Liu, Xuefeng Duan, Yanhong Wang and Tianmin Xu
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:222
  12. Acute myeloid leukemia (AML) patients bearing the ITD mutation in the tyrosine kinase receptor FLT3 (FLT3-ITD) present a poor prognosis and a high risk of relapse. FLT3-ITD is retained in the endoplasmic retic...

    Authors: Francesca Liccardo, Martyna Śniegocka, Claudia Tito, Alessia Iaiza, Tiziana Ottone, Mariadomenica Divona, Serena Travaglini, Maurizio Mattei, Rosella Cicconi, Selenia Miglietta, Giuseppe Familiari, Stefania Annarita Nottola, Vincenzo Petrozza, Luca Tamagnone, Maria Teresa Voso, Silvia Masciarelli…
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:223
  13. Lung cancer remains the leading cause of cancer-related deaths globally, and the survival rate remains low despite advances in diagnosis and treatment. The progression of lung cancer is a multifaceted and dyna...

    Authors: Naushad Ahmad Khan, Mohammad Asim, Kabir H. Biswas, Amani N Alansari, Harman Saman, Mohammad Zahid Sarwar, Kudaibergen Osmonaliev and Shahab Uddin
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:221
  14. Authors: E. C. de Heer, C. E. Zois, E. Bridges, B. van der Vegt, H. Sheldon, W. A. Veldman, M. C. Zwager, T. van der Sluis, S. Haider, T. Morita, O. Baba, C. P. Schröder, S. de Jong, A. L. Harris and M. Jalving
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:220

    The original article was published in Journal of Experimental & Clinical Cancer Research 2023 42:143

  15. The Makorin ring finger protein 1 (MKRN1) gene, also called RNF61, is located on the long arm of chromosome 7 and is a member of the RING finger protein family. The E3 ubiquitin ligase MKRN1 is closely linked to ...

    Authors: Yi Zhang, Qin-shan Li, Hong-lin Liu, Hong-ting Tang, Han-lin Yang, Dao-qiu Wu, Yu-ying Huang, Li-cheng Li, Li-hong Liu and Meng-xing Li
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:219

    The Correction to this article has been published in Journal of Experimental & Clinical Cancer Research 2023 42:240

  16. T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy, characterized by restricted cellular subsets with asymmetrically enriched leukemia initiating cell (LIC) activity. Nonethe...

    Authors: Emanuele Murgo, Elisabetta De Santis, Francesca Sansico, Valentina Melocchi, Tommaso Colangelo, Costanzo Padovano, Mattia Colucci, Annalucia Carbone, Beatrice Totti, Alireza Basti, Lisa Gottschlich, Angela Relogio, Nazzareno Capitanio, Fabrizio Bianchi, Gianluigi Mazzoccoli and Vincenzo Giambra
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:218
  17. Gemcitabine resistance has brought great challenges to the treatment of pancreatic cancer. The N6-methyladenosine (m6A) mutation has been shown to have a significant regulatory role in chemosensitivity; howeve...

    Authors: Kai Lin, Endi Zhou, Ting Shi, Siqing Zhang, Jinfan Zhang, Ziruo Zheng, Yuetian Pan, Wentao Gao and Yabin Yu
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:217
  18. In addition to specifically inducing tumor cell apoptosis, recombinant tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) has also been reported to influence the cancer immune microenvironme...

    Authors: Xupu Wang, Lizheng Wang, Wenmo Liu, Xinyao Liu, Xinyuan Jia, Xinyao Feng, Fangshen Li, Rui Zhu, Jiahao Yu, Haihong Zhang, Hui Wu, Jiaxin Wu, Chu Wang, Bin Yu and Xianghui Yu
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:216
  19. N7-methylguanosine (m7G) modification is, a more common epigenetic modification in addition to m6A modification, mainly found in mRNA capsids, mRNA interiors, transfer RNA (tRNA), pri-miRNA, and ribosomal RNA ...

    Authors: Mingpeng Zhang, Duo Kan, Boya Zhang, Xueqiao Chen, Chun Wang, Songmao Chen, Wenlong Gao, Zhao Yang, Yang Li, Yutong Chen, Shimiao Zhu, Simeng Wen, Yuanjie Niu and Zhiqun Shang
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:215
  20. Medulloblastoma (MB) is the most common cerebellar malignancy during childhood. Among MB, MYC-amplified Group 3 tumors display the worst prognosis. MYC is an oncogenic transcription factor currently thought to...

    Authors: Consuelo Pitolli, Alberto Marini, Marika Guerra, Marco Pieraccioli, Veronica Marabitti, Fernando Palluzzi, Luciano Giacò, Gianpiero Tamburrini, Francesco Cecconi, Francesca Nazio, Claudio Sette and Vittoria Pagliarini
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:214
  21. There is increasing evidence indicating the significant role of DDX5 (also called p68), acting as a master regulator and a potential biomarker and target, in tumorigenesis, proliferation, metastasis and treatm...

    Authors: Fengzhi Li, Xiang Ling, Sayan Chakraborty, Christos Fountzilas, Jianmin Wang, Anmbreen Jamroze, Xiaozhuo Liu, Pawel Kalinski and Dean G. Tang
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:213
  22. Authors: Matteo Centonze, Giusy Di Conza, Michael Lahn, Isabel Fabregat, Francesco Dituri, Isabella Gigante, Grazia Serino, Rosanna Scialpi, Livianna Carrieri, Roberto Negro, Elena Pizzuto and Gianluigi Giannelli
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:211

    The original article was published in Journal of Experimental & Clinical Cancer Research 2023 42:197

  23. Despite tremendous progress in deciphering breast cancer at the genomic level, the pronounced intra- and intertumoral heterogeneity remains a major obstacle to the advancement of novel and more effective treat...

    Authors: Nicole Anderle, Felix Schäfer-Ruoff, Annette Staebler, Nicolas Kersten, André Koch, Cansu Önder, Anna-Lena Keller, Simone Liebscher, Andreas Hartkopf, Markus Hahn, Markus Templin, Sara Y. Brucker, Katja Schenke-Layland and Christian Schmees
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:210
  24. Prostate cancer threatens the health of men over sixty years old, and its incidence ranks first among all urinary tumors among men. Enzalutamide remains the first-line drug for castration-resistant prostate ca...

    Authors: Qingzhuo Dong, Hui Qiu, Chiyuan Piao, Zhengxiu Li and Xiaolu Cui
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:209
  25. Authors: Bing Liu, Hongye Ma, Qianqian Liu, Yang Xiao, Shimeng Pan, Huimin Zhou and Li Jia
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:208

    The original article was published in Journal of Experimental & Clinical Cancer Research 2019 38:200

  26. The advances in cancer research achieved in the last 50 years have been remarkable and have provided a deeper knowledge of this disease in many of its conceptual and biochemical aspects. From viewing a tumor a...

    Authors: Alexandra Sala, James M. Cameron, Paul M. Brennan, Emma J. Crosbie, Tom Curran, Ewan Gray, Pierre Martin-Hirsch, David S. Palmer, Ihtesham U. Rehman, Nicholas J. W. Rattray and Matthew J. Baker
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:207
  27. The perineural invasion (PNI)-mediated inflammation of the tumor microenvironment (TME) varies among gastric cancer (GC) patients and exhibits a close relationship with prognosis and immunotherapy. Assessing t...

    Authors: Xunjun Li, Yiyun Wang, ZhongYa Zhai, Qingyi Mao, Dianjie Chen, Luxi Xiao, Shuai Xu, Qilin Wu, Keming Chen, Qiantong Hou, Qinglie He, Yuyang Shen, Manchun Yang, Zishan Peng, Siqing He, Xuanhui Zhou…
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:206
  28. Glioblastoma (GBM) is the most common malignant brain tumor and has “immunologically cold” features. Changing GBM to an “immunologically hot” tumor requires a strong trigger that induces initial immune respons...

    Authors: Tsutomu Nakazawa, Takayuki Morimoto, Ryosuke Maeoka, Ryosuke Matsuda, Mitsutoshi Nakamura, Fumihiko Nishimura, Noriko Ouji, Shuichi Yamada, Ichiro Nakagawa, Young Soo Park, Toshihiro Ito, Hiroyuki Nakase and Takahiro Tsujimura
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:205
  29. Prostate cancer(PCa) is the most commonly occurring male cancer in the USA. Abiraterone or Enzalutamide have been approved for the treatment of metastatic castration-resistant prostate cancer (CRPC). However, ...

    Authors: Linglong Yin, Yubing Ye, Ling Zou, Jinli Lin, Yi Dai, Yongming Fu, Youhong Liu, Yuchong Peng, Yingxue Gao, Yuxin Fu, Xuli Qi, Tanggang Deng, Songwei Zhang and Xiong Li
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:204
  30. TP53, encoding the tumor suppressor p53, is frequently mutated in various cancers, producing mutant p53 proteins (mutp53) which can exhibit neomorphic, gain-of-function properties. The latter transform p53 into a...

    Authors: Evangelos Pavlakis, Michelle Neumann, Nastasja Merle, Ronja Wieboldt, Michael Wanzel, Viviane Ponath, Elke Pogge von Strandmann, Sabrina Elmshäuser and Thorsten Stiewe
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:203
  31. The pancreatic microenvironment has a defensive role against cancer but it can acquire tumor-promoting properties triggered by multiple mechanisms including alterations in the equilibrium between proteases and...

    Authors: Andrea Resovi, Perla Persichitti, Laura Brunelli, Lucia Minoli, Patrizia Borsotti, Giulia Garattini, Matteo Tironi, Erica Dugnani, Miriam Redegalli, Giulia De Simone, Roberta Pastorelli, Maria Rosa Bani, Lorenzo Piemonti, Deane F. Mosher, Raffaella Giavazzi, Giulia Taraboletti…
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:201
  32. Advanced colorectal cancer (CRC) is difficult to treat. For that reason, the development of novel therapeutics is necessary. Here we describe a potentially actionable plasma membrane target, the amino acid tra...

    Authors: Juan Carlos Montero, Sofía del Carmen, Mar Abad, José M. Sayagués, Antonio Barbáchano, Asunción Fernández-Barral, Alberto Muñoz and Atanasio Pandiella
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:200
  33. Gemcitabine resistance (GR) is a significant clinical challenge in pancreatic adenocarcinoma (PAAD) treatment. Macrophages in the tumor immune-microenvironment are closely related to GR. Uncovering the macroph...

    Authors: Shengwei Jiang, Tingwei Deng, Huan Cheng, Weihan Liu, Dan Shi, Jiahui Yuan, Zhiwei He, Weiwei Wang, Boning Chen, Li Ma, Xianbin Zhang and Peng Gong
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:199
  34. Aberrant somatic genomic alteration including copy number amplification is a hallmark of cancer genomes. We previously profiled genomic landscapes of prostate cancer (PCa), yet the underlying causal genes with...

    Authors: Xiayun Yang, Qin Zhang, Shuxuan Li, Raman Devarajan, Binjie Luo, Zenglai Tan, Zixian Wang, Nikolaos Giannareas, Tomasz Wenta, Wenlong Ma, Yuqing Li, Yuehong Yang, Aki Manninen, Song Wu and Gong-Hong Wei
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:198
  35. Autotaxin (ATX) is a secreted enzyme that converts lysophosphatidylcholine to lysophosphatidic acid (LPA). LPA stimulates cell proliferation and migration and promotes wound repair following tissue damage. ATX...

    Authors: Matteo Centonze, Giusy Di Conza, Michael Lahn, Isabel Fabregat, Francesco Dituri, Isabella Gigante, Grazia Serino, Rosanna Scialpi, Livianna Carrieri, Roberto Negro, Elena Pizzuto and Gianluigi Giannelli
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:197

    The Correction to this article has been published in Journal of Experimental & Clinical Cancer Research 2023 42:211

  36. Genetic and metabolic heterogeneity are well-known features of cancer and tumors can be viewed as an evolving mix of subclonal populations, subjected to selection driven by microenvironmental pressures or drug...

    Authors: Daniele Boso, Martina Tognon, Matteo Curtarello, Sonia Minuzzo, Ilaria Piga, Valentina Brillo, Elisabetta Lazzarini, Jessica Carlet, Ludovica Marra, Chiara Trento, Andrea Rasola, Ionica Masgras, Leonardo Caporali, Fabio Del Ben, Giulia Brisotto, Matteo Turetta…
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:196
  37. Bone metastasis is a principal cause of mortality in patients with prostate cancer (PCa). Increasing evidence indicates that high expression of stromal interaction molecule 1 (STIM1)-mediated store-operated ca...

    Authors: Qianghua Zhou, Xu Chen, Kai Yao, Yangjie Zhang, Haixia He, Hao Huang, Hao Chen, Shengmeng Peng, Ming Huang, Liang Cheng, Qiang Zhang, Ruihui Xie, Kaiwen Li, Tianxin Lin and Hai Huang
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:195
  38. RNA binding proteins (RBPs)—regulated gene expression play a vital role in various pathological processes, including the progression of cancer. However, the role of RBP in hepatocellular carcinoma (HCC) remain...

    Authors: Shuang Tao, Shu-Juan Xie, Li-Ting Diao, Guo Lv, Ya-Rui Hou, Yan-Xia Hu, Wan-Yi Xu, Bin Du and Zhen-Dong Xiao
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:194
  39. Tissue-based biopsy is the present main tool to explore the molecular landscape of cancer, but it also has many limits to be frequently executed, being too invasive with the risk of side effects. These limits ...

    Authors: Daniele Santini, Andrea Botticelli, Antonio Galvano, Michele Iuliani, Lorena Incorvaia, Valerio Gristina, Chiara Taffon, Simone Foderaro, Elisa Paccagnella, Sonia Simonetti, Federico Fazio, Simone Scagnoli, Giulia Pomati, Francesco Pantano, Giuseppe Perrone, Elena De Falco…
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:193
  40. Platinum-drugs based chemotherapy in clinic increases the potency of tumor cells to produce M2 macrophages, thus leading to poor anti-metastatic activity and immunosuppression. Lysosome metabolism is critical ...

    Authors: Jing Ma, Ruijuan Ma, Xueke Zeng, Liming Zhang, Jianing Liu, Wei Zhang, Tao Li, Hanjing Niu, Guochen Bao, Chaojie Wang, Peng George Wang, Jiajia Wang, Xia Li, Taotao Zou and Songqiang Xie
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:192
  41. Circular RNAs (circRNAs) circularized by back-splicing of pre-mRNA are widely expressed and affected the proliferation, invasion and metastasis of bladder cancer (BCa). However, the mechanism underlying circRN...

    Authors: Yuanlong Li, Yao Kong, Mingjie An, Yuming Luo, Hanhao Zheng, Yan Lin, Jiancheng Chen, Jin Yang, Libo Liu, Baoming Luo, Jian Huang, Tianxin Lin and Changhao Chen
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:191
  42. Drug resistance limits the treatment effect of cisplatin-based chemotherapy in head and neck squamous cell carcinoma (HNSCC), and the underlying mechanism is not fully understood. The aim of this study was to ...

    Authors: Teng Xu, Yuemei Yang, Zhihong Chen, Jinsong Wang, Xiaolei Wang, Yang Zheng, Chao Wang, Yachen Wang, Zaiou Zhu, Xu Ding, Junbo Zhou, Gang Li, Hongchuang Zhang, Wei Zhang, Yunong Wu and Xiaomeng Song
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:190
  43. The 5th Workshop IRE on Translational Oncology was held in Rome (Italy) on 27–28 March at the IRCCS Regina Elena National Cancer Institute. This meeting entitled “The New World of RNA diagnostics and therapeut...

    Authors: Giovanni Blandino, Roberto Dinami, Marco Marcia, Eleni Anastasiadou, Brid M. Ryan, Alina Catalina Palcau, Luigi Fattore, Giulia Regazzo, Rosanna Sestito, Rossella Loria, Ana Belén Díaz Méndez, Maria Chiara Cappelletto, Claudio Pulito, Laura Monteonofrio, George A. Calin, Gabriella Sozzi…
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:189
  44. Lung cancer is one of the most frequent causes of cancer-related deaths worldwide. Drug repurposing and nano-drug delivery systems are attracting considerable attention for improving anti-cancer therapy. Serta...

    Authors: Ruolan Liu, Qiong Li, Siyuan Qin, Ling Qiao, Mei Yang, Shanshan Liu, Edouard C. Nice, Wei Zhang, Canhua Huang, Shaojiang Zheng and Wei Gao
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:188
  45. Prostate cancer is a major cause of cancer morbidity and mortality in men worldwide. Androgen deprivation therapy (ADT) has proven effective in early-stage androgen-sensitive disease, but prostate cancer gradu...

    Authors: Ioanna Mourkioti, Aikaterini Polyzou, Dimitris Veroutis, George Theocharous, Nefeli Lagopati, Emanuela Gentile, Vasiliki Stravokefalou, Dimitris-Foivos Thanos, Sophia Havaki, Dimitris Kletsas, Theocharis Panaretakis, Christopher J. Logothetis, Dimitris Stellas, Russell Petty, Giovanni Blandino, Angelos Papaspyropoulos…
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:187
  46. Authors: Yonghao Zhan, Junhao Lin, Yuchen Liu, Mingwei Chen, Xiaoying Chen, Chengle Zhuang, Li Liu, Wen Xu, Zhicong Chen, Anbang He, Qiaoxia Zhang, Xiaojuan Sun, Guoping Zhao and Weiren Huang
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:185

    The original article was published in Journal of Experimental & Clinical Cancer Research 2016 35:83

Annual Journal Metrics

  • 2022 Citation Impact
    11.3 - 2-year Impact Factor
    11.5 - 5-year Impact Factor
    1.870 - SNIP (Source Normalized Impact per Paper)
    2.413 - SJR (SCImago Journal Rank)

    2022 Speed
    4 days submission to first editorial decision for all manuscripts (Median)
    97 days submission to accept (Median)

    2022 Usage 
    2,694,347 downloads
    4,666 Altmetric mentions